Skip to main content

Table 1 Study population features

From: MRONJ in breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series

Pt

ID

Age

MRONJ- related drugs

Duration (months)

Cumulative dose (mg)

Systemic disease

Local risk factors for MRONJ

MRONJ site

MRONJ stage (AAOMS)

MRONJ stage (SICMF - SIPMO)

#1

62

Denosumab*

30

300

Maxilla

2

1

#2

88

Denosumab*

36

360

Hypertension

Dental extraction

Mandible

1

1

#3

59

Clodronate

24

19,800

Hypertension

Dental extraction

Mandible

1

1

#4

69

Alendronate

6

1680

Arthrosis

Periodontal disease

Mandible

2

1

#5

83

Denosumab*

12

120

Hypertension, diabetes

Mandible

1

2

#6

52

Alendronate

84

23,520

Dental extraction

Mandible

2

2

#7

55

Denosumab*

24

240

Periodontal disease

Maxilla

1

2

#8

52

Denosumab*

24

240

Mandible

1

2

#9

67

Oral ibandronate

10

1500

Dental extraction

Mandible

2

2

#10

58

Denosumab*

84

840

Peri-implantitis

Mandible

3

3

#11

68

Clodronate

84

16,800

Mandible

3

3

#12

72

Alendronate

18

5040

Hypertension

Dental extraction

Maxilla

3

3

#13

69

Alendronate

52

14,560

Hypertension

Maxilla

3

3

#14

81

Denosumab*

24

240

Hypertension, diabetes

Dental extraction

Mandible

2

2

#15

78

Denosumab*

24

240

Hypertension

Periodontal disease

Mandible

1

2

  1. *Denosumab: 60 mg s.c. every 6 months